Daiichi, ArQule (ARQL) Report ARQ 197 Missed Endpoint in Phase 2
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
ArQule's (ARQL) Tivantinib Still Has Potential in HCC
January 11, 2013 1:37 PM ESTShares of ArQule Inc. (Nasdaq: ARQL) declined Friday morning after it announced disappointing top-line results from a Phase 2 signal generation trial of tivantinib for used in combination with irinotecan and cetuximab in patients with refractory or relapsed colorectal cancer (CRC). Despite the setback, Burrill... More
Arqule, Inc. (ARQL) trading halted with news pending
January 11, 2013 7:25 AM ESTArqule, Inc. (NASDAQ: ARQL) trading halted with news pending.... More
